ECE2022 Poster Presentations Diabetes, Obesity, Metabolism and Nutrition (202 abstracts)
1VHIR - Vall dHebron Institut de Recerca, Diabetes and Metabolism, Barcelona, Spain; 2Hospital Universitari Vall dHebron, Pathology, Barcelona, Spain
Low plasma sex hormone-binding globulin (SHBG) levels are present in fatty liver disease, which represent a spectrum of diseases ranging from hepatocellular steatosis through steatohepatitis to fibrosis and irreversible cirrhosis. We have previously determined that fat accumulation reduces SHBG production in different non-alcoholic fatty liver disease (NAFLD) mouse models and that SHBG plays an active role in the development of this disease. In the present work, we are interested in elucidating the molecular mechanisms reducing SHBG plasma levels in liver fibrosis development. To do so, in vivo studies were performed using the human SHBGtransgenic mice developing liver fibrosis induced by carbon tetrachloride (CCl4). Our results showed that CCl4 induced liver fibrosis and decreased SHBG production by reducing hepatocyte nuclear factor 4 alpha (HNF-4α). The SHBG reduction could be influenced by the increase in TGF-β1 levels, which were elevated in mice developing liver fibrosis. Results obtained in human SHBG transgenic mice showed that TGF-β1 reduced significantly SHBG mRNA and protein levels through TGF-β1 receptor I via STAT3 signaling pathway, resulting in a transcriptional repression of the SHBG gene. Overall, TGF-β1 is a new factor downregulating hepatic SHBG production in liver fibrosis development.